Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
- Submitting institution
-
Queen's University of Belfast
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 217557144
- Type
- D - Journal article
- DOI
-
10.1016/S2213-2600(20)30397-0
- Title of journal
- The Lancet Respiratory Medicine
- Article number
- -
- First page
- 57
- Volume
- 9
- Issue
- 1
- ISSN
- 2213-2600
- Open access status
- Compliant
- Month of publication
- September
- Year of publication
- 2020
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
23
- Research group(s)
-
-
- Citation count
- -
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to carrying out the study and to analysis and interpretation of study data. The author helpd draft the output and critque the output for important intellectual content
- Non-English
- No
- English abstract
- -
